Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Challenges and opportunities for tumor-infiltrating lymphocytes in melanoma

Karijn Suijkerbuijk • 25 Oct 2026
ESMO 2026
Melanoma Skin Cancer

Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands, comments on the limitations and potential of tumor-infiltrating lymphocytes (TIL) therapy, highlighting that not all patients are eligible due to requirements such as resectable lesions and tolerance for chemotherapy and IL-2. Ongoing studies will provide insights into the optimal use of TIL, including its potential combination with checkpoint inhibitors and its role in first-line treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Karijn Suijkerbuijk

iFOCUS: histotripsy boosting immune checkpoint inhibition in solid tumors
0:54
iFOCUS: histotripsy boosting immune checkpoint inhibition in solid tumors
Karijn Suijkerbuijk • 25 Oct 2026
MIZAR-003: extended follow-up of GC101 TIL therapy in advanced melanoma
1:33
MIZAR-003: extended follow-up of GC101 TIL therapy in advanced melanoma
Karijn Suijkerbuijk • 25 Oct 2026
Managing acute and long-term side effects in checkpoint inhibitors for melanoma
0:34
Managing acute and long-term side effects in checkpoint inhibitors for melanoma
Karijn Suijkerbuijk • 16 Sep 2024
NADINA: promising neoadjuvant immunotherapy strategies for melanoma
2:58
NADINA: promising neoadjuvant immunotherapy strategies for melanoma
Karijn Suijkerbuijk • 16 Sep 2024

Related Videos

Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
1:49
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
Paolo Ascierto • 23 Oct 2026
Comparing the current roles and toxicities of TILs and TCR cell therapy
2:53
Comparing the current roles and toxicities of TILs and TCR cell therapy
Marco Donia • 26 Oct 2026
iFOCUS: histotripsy boosting immune checkpoint inhibition in solid tumors
0:54
iFOCUS: histotripsy boosting immune checkpoint inhibition in solid tumors
Karijn Suijkerbuijk • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals